Compare · INSM vs NVO
INSM vs NVO
Side-by-side comparison of Insmed Incorporated (INSM) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INSM and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 9.5x INSM ($23.48B).
- Over the past year, INSM is up 5.6% and NVO is down 21.8% - INSM leads by 27.3 points.
- INSM has been more active in the news (11 items in the past 4 weeks vs 5 for NVO).
- Both have 25 recent analyst ratings on file.
- Company
- Insmed Incorporated
- Novo Nordisk A/S
- Price
- $108.28+0.73%
- $50.31-2.25%
- Market cap
- $23.48B
- $222.81B
- 1M return
- +13.38%
- +15.47%
- 1Y return
- +5.57%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 11
- 5
- Recent ratings
- 25
- 25
Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest INSM
- Insmed Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
- Chair and CEO Lewis William exercised 10,699 shares at a strike of $24.94 and sold $1,256,084 worth of shares (10,699 units at $117.40) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Flammer Martina M.D. exercised 12,302 shares at a strike of $25.80 and sold $1,352,932 worth of shares (12,302 units at $109.98) as part of a pre-agreed trading plan (SEC Form 4)
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- FDA Approval for ARIKAYCE KIT issued to INSMED INC
- Chair and CEO Lewis William sold $2,210,763 worth of shares (21,398 units at $103.32) as part of a pre-agreed trading plan and exercised 21,398 shares at a strike of $24.94 (SEC Form 4)
- SVP, GM, Global Respiratory Butera Samuele was granted 7,342 shares (SEC Form 4)
- SEC Form 3 filed by new insider Butera Samuele
- Chief Legal Officer Smith Michael Alexander sold $173,051 worth of shares (1,806 units at $95.82) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 37,648 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S